AVTX: Avalo Therapeutics, Inc. Price to Sales

Symbol and logo of brand Avalo Therapeutics Inc. (AVTX)

Developing therapies for immune pathologies requires massive investment, as evidenced by the price-to-sales ratio chart. The value of 7035.20 represents the current level of this metric. To combat funding shortages, Avalo Therapeutics, Inc (AVTX) is restructuring its asset portfolio. Future success depends on FDA approval of its patent-protected monoclonal antibodies, which will enable the treatment of severe systemic inflammation.

Market Cap to Revenue: avalotx.com (AVTX) for 07/04/2022 - 11/16/2026

Metric breakdowns and analytics for Avalo Therapeutics, Inc (AVTX)

- stock price and consensus target price:
Fundamental company analysis:AVTX - Avalo Therapeutics Inc.
Signature product of Avalo Therapeutics Inc

The P/S multiple reflects the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of income. For Avalo Therapeutics, Inc (AVTX), whose success depends on FDA approval of monoclonal antibodies, the company's P/S chart serves as an indicator of speculative expectations, where deviations from historical averages signal risks of overvaluing the potential of future patents.

Who Avalo Therapeutics, Inc competes with

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price to Sales Tiziana Life Sciences Ltd. (TLSA)|Market Cap to Revenue CABA|Ventyx Biosciences (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|Market Cap to Revenue Eledon Pharmaceuticals ELDN|Price-to-Revenue Ratio Agenus, Inc. AGEN|P/S Multiple Climb Bio Inc. CLYM|ZURA - Price-to-Revenue Ratio|Price-to-Sales Ratio ATYR|ADAG (Adagene Inc.) - Market Cap to Revenue|ImageneBio Inc (IMA) - P/S Multiple|Price-to-Revenue Ratio Shattuck Therapeutics|Market Cap to Revenue equilliumbio.com (EQ)|P/S Multiple CNTB|Price-to-Revenue Coefficient Immunic Therapeutics|P/S Multiple ATRA (Atara Biotherapeutics, Inc.)|IFRX - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio X4 Pharmaceuticals, Inc. (XFOR)|ACET (adicetbio.com) - Market Cap to Revenue Ratio|CELU: P/S Multiple|INMB - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Barinthus Biotherapeutics plc|KZR: Market Capitalization-to-Revenue Ratio|P/S Multiple SABS|AKTX (Akari Therapeutics Plc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple